Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
暂无分享,去创建一个
S. Larson | R. Tuttle | R. Leboeuf | R. Grewal | Norma A Lopez | M. Brokhin | Gal Omry | S. Minkowitz
[1] A. Pinchera,et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.
[2] E. Papini,et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. , 2009, European journal of endocrinology.
[3] R. Wahl,et al. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. , 2009, The Journal of clinical endocrinology and metabolism.
[4] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[5] D. Barbaro,et al. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[7] S. Larson,et al. Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.
[8] T. Pilli,et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.
[9] L. Duntas,et al. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. , 2008, Thyroid : official journal of the American Thyroid Association.
[10] G. Mariani,et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. , 2003, The Journal of clinical endocrinology and metabolism.